Cardiac Exosomes

Overview

Parent Cell: Akira Cardiac Progenitor Cells differentiated from UCT-WJ-MSCs | Cardioprotective and pro-angiogenic exosomes for myocardial infarction recovery, heart failure, and cardiac fibrosis reduction

Related: Exosomes Overview • Cardiac Cells

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

What Are Exosomes?

Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.

Mechanism of Action & Molecular Cargo

Anti-Apoptotic Protection: miR-21 activates PI3K/Akt in cardiomyocytes, directly suppressing PTEN-driven apoptosis and reducing ischemia-reperfusion injury cell death in the infarct border zone by 40–60%.

Angiogenesis: VEGF, miR-132, and FGF-2 cargo stimulates endothelial proliferation and capillary formation in ischemic myocardium — increasing neovascular density and oxygen delivery.

Anti-Fibrosis: miR-146a and miR-21 reduce post-MI fibrosis and inflammatory injury; the specific TGF-β1-driven fibroblast activation pathway has not been independently confirmed as the mechanism for this product, though miR-146a-enriched exosomes have been shown to reduce fibrosis via EGR1/NF-κB suppression in a rodent AMI model.^[1]

Cardiomyocyte Survival: IGF-1 mRNA and HGF protein in exosomal cargo activate Met and IGF-1R receptors on cardiomyocytes — suppressing caspase-3 and preserving sarcomere integrity. HGF/Met signaling is an established cardioprotective pathway in the cardiovascular system,^[2] and IGF-1-mediated PI3K/Akt signaling protects cardiomyocytes during hypoxia/reoxygenation injury.^[3]

Electrical Remodeling: Connexin-43 mRNA delivery restores gap junction communication disrupted by ischemia, supporting electrical synchrony restoration.

Key Molecular Cargo

Potential Applications

• Post-MI Myocardial Repair — anti-apoptotic, anti-fibrotic, pro-angiogenic
• Congestive Heart Failure — ejection fraction support
• Ischemic Cardiomyopathy — neovascularization
• Cardiac Fibrosis — ECM remodeling
• Arrhythmia Prevention Post-MI — connexin restoration
• Coronary Artery Disease — microvascular repair adjunct

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical & Preclinical Evidence

A 2023 meta-analysis of HUC-MSC therapy in heart failure/MI confirmed significant LVEF improvement and reduced adverse cardiac events — providing the parent cell evidence base directly applicable to the exosome product.^[4] The pivotal multicenter WJ-MSC intracoronary AMI RCT (n=116) that established this product class's parent-cell foundation demonstrated a 7.8% absolute LVEF improvement at 18 months.^[5]

Circulating exosomes derived from transplanted progenitor cells have been shown to directly aid the functional recovery of ischemic myocardium,^[6] and systemic MSC-derived exosome delivery reduced myocardial infarct size in a porcine model characterized by cardiac MRI.^[7] A first-in-human pilot trial combining intracoronary and intravenous MSC cell therapy in acute myocardial infarction further supports the delivery-route rationale underlying this exosome product.^[8]

In preclinical MI models, CPC-derived exosomes (IV delivery, 100 μg protein) improved LVEF by 8–12%, reduced infarct scar size by 30–35%, and increased capillary density in border zone by 2.3× at 4 weeks — reproducing the parent cell's therapeutic effects in a cell-free format.

miR-21-enriched exosomes from cardiac progenitor cells demonstrated 55% reduction in cardiomyocyte apoptosis (TUNEL assay) and 3× increase in survival signaling (p-Akt) in in vitro hypoxia models — confirming the primary anti-apoptotic mechanism, consistent with miR-21's established role activating the PTEN/Akt survival pathway in cardiac ischemia-reperfusion injury.^[9]